The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

被引：62
|
作者：
Thanendrarajan, Sharmilan [1 ]
Tian, Erming [1 ]
Qu, Pingping [2 ]
Mathur, Pankaj [1 ]
Schinke, Carolina [1 ]
van Rhee, Frits [1 ]
Zangari, Maurizio [1 ]
Rasche, Leo [1 ]
Weinhold, Niels [1 ]
Alapat, Daisy [3 ]
Bellamy, William [3 ]
Ashby, Cody [1 ]
Mattox, Sandra [1 ]
Epstein, Joshua [1 ]
Yaccoby, Shmuel [1 ]
Barlogie, Bart [1 ]
Hoering, Antje [2 ]
Bauer, Michael [1 ]
Walker, Brian A. [1 ]
Davies, Faith E. [1 ]
Morgan, Gareth J. [1 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst, Little Rock, AR 72205 USA
[2] Cancer Res & Biostat Seattle, Seattle, WA USA
[3] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 09期
关键词：
IN-SITU HYBRIDIZATION; TOTAL THERAPY; HIGH-RISK; EXPRESSION; RELAPSE; SYSTEM;
D O I：
10.3324/haematol.2017.168872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E364 / E367
页数：4
相关论文
共 8 条
  • [1] Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
    Hao, Suyang
    Lin, Pei
    Medeiros, L. Jeffrey
    Fang, Lianghua
    Carballo-Zarate, Adrian A.
    Konoplev, Sergej N.
    Sargent, Rachel L.
    Weber, Donna M.
    Thomas, Sheeba K.
    Manasanch, Elisabet E.
    Orlowski, Robert Z.
    Lu, Xinyan
    MODERN PATHOLOGY, 2017, 30 (10) : 1378 - 1386
  • [2] How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam, Constantine S.
    Stilgenbauer, Stephan
    LEUKEMIA & LYMPHOMA, 2015, 56 (03) : 587 - 593
  • [3] Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
    De Ramon, Cristina
    Rojas, Elizabeta A.
    Cardona-Benavides, Ignacio J.
    Mateos, Maria-Victoria
    Corchete, Luis A.
    Gutierrez, Norma C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (03) : 344 - 354
  • [4] Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment
    Popek-Marciniec, Sylwia
    Styk, Wojciech
    Wojcierowska-Litwin, Magdalena
    Chocholska, Sylwia
    Szudy-Szczyrek, Aneta
    Samardakiewicz, Marzena
    Swiderska-Kolacz, Grazyna
    Czerwik-Marcinkowska, Joanna
    Zmorzynski, Szymon
    CANCERS, 2023, 15 (19)
  • [5] Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
    Neben, Kai
    Lokhorst, Henk M.
    Jauch, Anna
    Bertsch, Uta
    Hielscher, Thomas
    van der Holt, Bronno
    Salwender, Hans
    Blau, Igor W.
    Weisel, Katja
    Pfreundschuh, Michael
    Scheid, Christof
    Duehrsen, Ulrich
    Lindemann, Walter
    Schmidt-Wolf, Ingo G. H.
    Peter, Norma
    Teschendorf, Christian
    Martin, Hans
    Haenel, Mathias
    Derigs, Hans G.
    Raab, Marc S.
    Ho, Anthony D.
    van de Velde, Helgi
    Hose, Dirk
    Sonneveld, Pieter
    Goldschmidt, Hartmut
    BLOOD, 2012, 119 (04) : 940 - 948
  • [6] The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma
    Sreedharanunni, Sreejesh
    Singla, Shelly
    Balakrishnan, Anand
    Singh, Archana
    Jamwal, Manu
    Singh, Namrata
    Singh, Charanpreet
    Jandial, Aditya
    Lad, Deepesh
    Sharma, Praveen
    Sachdeva, Man updesh singh
    Malhotra, Pankaj
    Das, Reena
    PATHOLOGY, 2024, 56 (04) : 556 - 564
  • [7] Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
    Zenz, Thorsten
    Haebe, Sonja
    Denzel, Tina
    Mohr, Julia
    Winkler, Dirk
    Buehler, Andreas
    Sarno, Antonio
    Groner, Silja
    Mertens, Daniel
    Busch, Raymonde
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2009, 114 (13) : 2589 - 2597
  • [8] Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study
    Cohen, Yael C.
    Saranga, Avi
    Gatt, Moshe E.
    Lavi, Noa
    Ganzel, Chezi
    Magen, Hila
    Avivi, Irit
    Tadmor, Tamar
    Suriu, Celia
    Dolberg, Osnat Jarchowsky
    Papushado, Amitai
    Trestman, Svetlana
    Ram, Ron
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (06) : 810 - 815
1